KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
KALA BIO, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.19+0.00 (+1.42%)
Close on Oct 19, 2026
- Market cap
- $14.28K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$65.3074 (−99.71%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
KALA BIO, Inc. reported revenue of $0 for fiscal 2025.
Revenue
$0
FY2025
Operating income
-$20.99M
TTM Q2 2026
EPS, diluted
-$165.50
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $14.28K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$10.08M
- EPS, diluted
- -$165.50
- Book value per share
- $121.95
- Diluted shares
- 0M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$20.99M
Net income
-$10.08M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months